677 related articles for article (PubMed ID: 10958782)
1. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.
Steidler L; Hans W; Schotte L; Neirynck S; Obermeier F; Falk W; Fiers W; Remaut E
Science; 2000 Aug; 289(5483):1352-5. PubMed ID: 10958782
[TBL] [Abstract][Full Text] [Related]
2. Immunology. Therapeutic manipulation of gut flora.
Shanahan F
Science; 2000 Aug; 289(5483):1311-2. PubMed ID: 10979858
[TBL] [Abstract][Full Text] [Related]
3. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein.
Foligne B; Dessein R; Marceau M; Poiret S; Chamaillard M; Pot B; Simonet M; Daniel C
Gastroenterology; 2007 Sep; 133(3):862-74. PubMed ID: 17678918
[TBL] [Abstract][Full Text] [Related]
4. Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice.
Nishitani Y; Tanoue T; Yamada K; Ishida T; Yoshida M; Azuma T; Mizuno M
Int Immunopharmacol; 2009 Nov; 9(12):1444-51. PubMed ID: 19733697
[TBL] [Abstract][Full Text] [Related]
5. Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model.
del Carmen S; Martín Rosique R; Saraiva T; Zurita-Turk M; Miyoshi A; Azevedo V; de Moreno de LeBlanc A; Langella P; Bermúdez-Humarán LG; LeBlanc JG
J Clin Gastroenterol; 2014; 48 Suppl 1():S12-7. PubMed ID: 25291117
[TBL] [Abstract][Full Text] [Related]
6. Paracellular entry of interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice.
Waeytens A; Ferdinande L; Neirynck S; Rottiers P; De Vos M; Steidler L; Cuvelier CA
Inflamm Bowel Dis; 2008 Apr; 14(4):471-9. PubMed ID: 18092343
[TBL] [Abstract][Full Text] [Related]
7. Oral delivery of Lactococcus lactis that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice.
Shigemori S; Watanabe T; Kudoh K; Ihara M; Nigar S; Yamamoto Y; Suda Y; Sato T; Kitazawa H; Shimosato T
Microb Cell Fact; 2015 Nov; 14():189. PubMed ID: 26608030
[TBL] [Abstract][Full Text] [Related]
8. Preventative delivery of IL-35 by Lactococcus lactis ameliorates DSS-induced colitis in mice.
Wang J; Tian M; Li W; Hao F
Appl Microbiol Biotechnol; 2019 Oct; 103(19):7931-7941. PubMed ID: 31456001
[TBL] [Abstract][Full Text] [Related]
9. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice.
Vandenbroucke K; Hans W; Van Huysse J; Neirynck S; Demetter P; Remaut E; Rottiers P; Steidler L
Gastroenterology; 2004 Aug; 127(2):502-13. PubMed ID: 15300583
[TBL] [Abstract][Full Text] [Related]
10. Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation.
Martín R; Chain F; Miquel S; Natividad JM; Sokol H; Verdu EF; Langella P; Bermúdez-Humarán LG
Hum Vaccin Immunother; 2014; 10(6):1611-21. PubMed ID: 24732667
[TBL] [Abstract][Full Text] [Related]
11. Lactococcus lactis carrying the pValac eukaryotic expression vector coding for IL-4 reduces chemically-induced intestinal inflammation by increasing the levels of IL-10-producing regulatory cells.
Souza BM; Preisser TM; Pereira VB; Zurita-Turk M; de Castro CP; da Cunha VP; de Oliveira RP; Gomes-Santos AC; de Faria AM; Machado DC; Chatel JM; Azevedo VA; Langella P; Miyoshi A
Microb Cell Fact; 2016 Aug; 15(1):150. PubMed ID: 27576902
[TBL] [Abstract][Full Text] [Related]
12. Lactococcus lactis carrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis.
Zurita-Turk M; Del Carmen S; Santos AC; Pereira VB; Cara DC; Leclercq SY; de LeBlanc Ad; Azevedo V; Chatel JM; LeBlanc JG; Miyoshi A
BMC Biotechnol; 2014 Aug; 14():73. PubMed ID: 25106058
[TBL] [Abstract][Full Text] [Related]
13. Actobiotics as a novel method for cytokine delivery.
Steidler L; Rottiers P; Coulie B
Ann N Y Acad Sci; 2009 Dec; 1182():135-45. PubMed ID: 20074282
[TBL] [Abstract][Full Text] [Related]
14. Microbial therapeutics for acute colitis based on genetically modified Lactococcus lactis hypersecreting IL-1Ra in mice.
Namai F; Shigemori S; Ogita T; Sato T; Shimosato T
Exp Mol Med; 2020 Sep; 52(9):1627-1636. PubMed ID: 32989233
[TBL] [Abstract][Full Text] [Related]
15. Delivery of therapeutic proteins through Lactococcus lactis.
Neirynck S; Steidler L
Biotechnol Genet Eng Rev; 2006; 22():253-66. PubMed ID: 18476334
[No Abstract] [Full Text] [Related]
16. Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa.
Simčič S; Berlec A; Stopinšek S; Štrukelj B; Orel R
World J Microbiol Biotechnol; 2019 Feb; 35(3):45. PubMed ID: 30810891
[TBL] [Abstract][Full Text] [Related]
17. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10.
Steidler L; Neirynck S; Huyghebaert N; Snoeck V; Vermeire A; Goddeeris B; Cox E; Remon JP; Remaut E
Nat Biotechnol; 2003 Jul; 21(7):785-9. PubMed ID: 12808464
[TBL] [Abstract][Full Text] [Related]
18. Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci.
Bermúdez-Humarán LG; Motta JP; Aubry C; Kharrat P; Rous-Martin L; Sallenave JM; Deraison C; Vergnolle N; Langella P
Microb Cell Fact; 2015 Feb; 14():26. PubMed ID: 25889561
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic effects of Lonicera japonica extract on dextran sulphate sodium-induced colitis in a mouse model by the inhibition of the Th1/Th17 response.
Park JW; Bae H; Lee G; Hong BG; Yoo HH; Lim SJ; Lee K; Kim J; Ryu B; Lee BJ; Bae J; Lee H; Bu Y
Br J Nutr; 2013 Jan; 109(2):283-92. PubMed ID: 22569277
[TBL] [Abstract][Full Text] [Related]
20. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
